CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion
American Journal of Hematology, EarlyView.
Authors: Niedźwiecki M, Budziło O, Zieliński M, Adamkiewicz-Drożyńska E, Maciejka-Kembłowska L, Szczepański T, Trzonkowski P Abstract CD4+CD25highCD127low/-FoxP3+ regulatory T cells (Tregs) are currently under extensive investigation in childhood acute lymphoblastic leukemia (ALL) and in other human cancers. Usually, Treg cells maintain the immune cell homeostasis. This small subset of T cells has been, in fact, considered to be involved in the pathogenesis of autoimmune diseases and progression of acute and chronic leukemias. However, whether Treg dysregulation in CLL and ALL plays a key role or it rather r...
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Therapy related myeloid neoplasm (t-MN) is an emerging challenge in the current era given that newer therapies are improving the life expectancy of patients diagnosed with cancer. This condition arises as a result of exposure to prior chemotherapy or radiotherapy used to treat malignant or non-malignant conditions. The World Health Organization (WHO) 2001 classification of tumors of hematopoietic and lymphoid tissues had initially described this disorder with two subtypes – therapy related acute myeloid leukemia (t-AML) and therapy related myelodysplastic syndrome (t-MDS) 1.
T cell acute lymphoblastic leukemia (T-ALL) accounts for approximately 15% and 25% of newly diagnosed ALL cases in children and adults, respectively [1,2]. In contrast to B cell acute lymphoblastic leukemia (B-ALL), T-ALL is associated with a higher frequency of relapse and less favourable outcomes. Minimal residual disease (MRD) may persist after treatment and eventually lead to clinical relapse.
The PD-1/PD-L1 (programmed cell death) pathway is an immune checkpoint, which protects normal tissues but can also prevent anti-tumor immune response. The FDA approvals of checkpoint inhibitors constitutes a major advance in the immunotherapy of cancer . Chronic myeloid leukemia (CML) is an example of successful use of tyrosine kinase inhibitors (TKIs). Blockade of oncogenic BCR-ABL1 kinase activity translated into an impressive control of the disease. CML is also known to be responsive to immunotherapy and long-term eradication of CML has been achieved by allogeneic hematopoietic stem cell transplantation .
Relapse is the most important cause of failure in the treatment of acute myeloid leukemia (AML). The European Leukemia Net (ELN) recommends allogeneic stem cell transplantation (alloSCT) in AML patients in first complete remission after a careful risk-benefit assessment1. Here, disease specific and transplantation specific risk factors have to be evaluated before a recommendation for an alloSCT can be given. Generally, alloSCT is recommended if disease relapse risk exceeds 35 to 40% without the procedure.
We describe a case of eosinophil ia and elevated IgE in a 61-year-old gentleman who was subsequently diagnosed with B-cell chronic lymphocytic leukemia (B-CLL). His eosinophilia and immunoglobulin E (IgE) levels declined significantly after initiating ibrutinib therapy for B-CLL.
Enumeration of blasts in the bone marrow is critical for diagnostic, prognostic, and therapeutic response evaluation in myelodysplastic syndromes, myeloproliferative neoplasms and acute leukemias. However, few studies have examined the accuracy and precision of marrow blast counting using standard microscopic procedures. In our study, four experienced hematopathologists evaluated blast percentages in marrow using either differential counts on aspirate smears or visual estimates on CD34-stained trephine biopsies.
The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells, Published online: 15 July 2018; doi:10.1038/s41375-018-0201-2The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
To the editor,